Should older head and neck patients be treated differently?  by Dequanter, D. et al.
European Annals of Otorhinolaryngology, Head and Neck diseases (2011) 128, 165—168
ORIGINAL ARTICLE
Should older head and neck patients be treated
differently?
D. Dequanter ∗, M. Shahla, P. Paulus, E. Boutremans, P. Lothaire
Service de chirurgie Maxillofacial, CHU Charleroi, 706, rue de Gozée, 6110 Montigny-le-Tilleul, Belgium
Available online 18 May 2011
KEYWORDS
Upper aerodigestive
tract cancer;
Elderly;
Treatment
Abstract
Objectives: Growing life expectancy is resulting in an increasing number of elderly patients with
upper aero digestive tract tumor. The objective of this study was to assess the appropriateness
of aggressive curative treatment for these older patients.
Patients and Methods: Patients over the age of 70 years, with head and neck squamous cell
carcinoma (HNSCC) of the oral cavity, pharynx or larynx, primarily treated in our department
between 2005 and 2007, were assessed retrospectively at 36 months’ follow-up. Demographics,
comorbidity and treatment strategies and their associated morbidity and mortality were
reviewed.
Results: Thirty-two males and 12 females with a median age of 77 years (range, 70—88 yrs)
were given curative treatment. The majority presented with a least one comorbidity. Seven
had a history of myocardial ischemia, 15 of chronic obstructive bronchopathy, and 10 of type-2
diabetes; 17 were under treatment for arterial hypertension, four had chronic renal insufﬁ-
ciency, and two had cirrhosis. Nine patients received radiation therapy alone; 18, concomitant
chemoradiotherapy; 14, surgery with adjuvant chemoradiotherapy; three were treated by sal-
vage surgery after failure of radiation therapy. In the 44 patients, there were 12 deaths: seven
from recurrence, two from treatment complications, one from MI, one from peritonitis and one
from pneumonia. At 36 months’ follow-up, 32 of the 44 patients were alive.
Conclusion: HNSCC is a serious disease that often necessitates aggressive treatment. All
patients who are medically eligible should receive curative treatment, without age being an
exclusion criterion. Taking comorbidity into account, on the other hand, enables treatment
options to be optimized.
© 2011 Elsevier Masson SAS. All rights reserved.∗ Corresponding author.
E-mail address: didier.dequanter@chu-charleroi.be
(D. Dequanter).
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doi:10.1016/j.anorl.2010.12.009ntroductionew surgical techniques, notably in the ﬁeld of reconstruc-
ive surgery, improved medical treatment and advances in
nesthesiology allow more aggressive management of upper
erodigestive tract (UAT) tumor, matching the aggressive-
served.
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ess of the pathology. Can this aggressive attitude be applied
n elderly patients? The question needs to be raised and is of
reat relevance in developed countries given the aging of the
atient population. As life expectancy increases along with
he number of malignancies diagnosed at ages exceeding
0 years, the number of patients will continue to rise.
The present study sought to assess the appropriateness
f aggressive treatment in elderly UAT tumor patients.
atients and Methods
he clinical records of patients over the age of 70 years,
resenting with UAT tumor of the oral cavity, pharynx or
arynx were reviewed. Baseline clinical status was assessed
n the ASA classiﬁcation, of proven effectiveness for precise
etermination of expected short and medium term mor-
idity in elderly patients. Treatment options were surgery,
adiation therapy and concomitant chemoradiotherapy.
emographics, comorbidity and treatment strategies and
heir associated morbidity and mortality were assessed.
esults
hirty-twomen and 12 women, with amedian age of 77 years
range, 70—88 yrs) were treated. Twenty-three presented
ith stage IV UAT tumor, ﬁve with stage III, 13 with stage II
nd three with stage I (Fig. 1).
Forty-ﬁve percent of tumors involved the larynx, 23%he hypopharynx, 15% the oral cavity, 6% the oropharynx
nd 6% were of unknown origin (Fig. 2). Patient distribu-
ion according to tumor stage and location is presented in
able 1.
igure 1 Patient distribution according to tumor stage at
iagnosis.
igure 2 Patient distribution according to tumor location.
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A majority of patients presented with at least one comor-
idity factor: seven with history of myocardial ischemia, 15
f chronic obstructive bronchopathy, and 10 of type-2 dia-
etes; 17 were under treatment for arterial hypertension, 4
ad chronic renal insufﬁciency, and two had cirrhosis; three
ad had stroke.
Nine patients received radiation therapy (65—70Gy)
lone; 18, concomitant chemoradiotherapy; 14, surgery
ith adjuvant chemoradiotherapy; three were treated by
alvage surgery after failure of radiation therapy.
In the 18 patients receiving concomitant chemoradio-
herapy, no fatal complications occurred. Grade-3 mucositis
as diagnosed in 22% of cases and grade-3 leukocytopenia
n 4%. Global response to treatment on clinical, endoscopic
nd radiologic assessment was 88%.
There was no postoperative mortality in patients
anaged by ﬁrst-intention surgery. One patient treated
y laryngectomy associated to bilateral ganglion curage
eveloped a ﬁstula, which resolved spontaneously. One
atient developed pneumopathy, treated by antibiotherapy.
There were 12 deaths among the 44 patients. Seven
atients showed locoregional recurrence; two died of a
reatment-linked complication, one of myocardial infarc-
ion, one from peritonitis and one from pneumopathy
omplicated by septic shock.
There was no mortality in stage-I patients (n = 3). Of the
tage-II patients (n = 13), one died of pneumopathy, without
igns of recurrence, one of MI and one, who showed locore-
ional recurrence, died despite salvage chemoradiotherapy.
here was no mortality in stage-III patients (n = 5). Of the
tage-IV patients (n = 23), 14 were alive without signs of
ecurrence at the time of writing, six died following recur-
ence, two following a treatment-linked complication, and
ne following peritonitis.
At 12 months’ FU, 35 of the 44 patients were alive, and
2 at 36months.
iscussion
AT tumor requires an aggressive attitude if curative treat-
ent is intended. Age has frequently been seen as an
xclusion criterion for such an approach.
However, in a society in which the population is observed
o be aging, an increasing number of elderly UAT tumor
atients, considered unsuited for appropriately aggressive
reatment, can be expected [1,2]. Reassessment of treat-
ent strategies is therefore certainly needed in this age
roup [3].
The current opinion in the literature is divided as to treat-
ent recommendations (and to associated complications)
or elderly UAT tumor patients.
Radiation therapy is, however, an obvious option in
lderly subjects [4]. While their clinical characteristics and
reatment response patterns differ from those found in the
ounger population, their tolerance does not. Associated
cute and chronic toxicity is identical in both age groups,
s is efﬁcacy in terms of locoregional control. In the present
eries, nine patients were managed by radiation therapy
lone. Compliance was acceptable, and the intended radia-
ion dose could be administered in all cases. No courses of
reatment had to be interrupted due to acute toxicity.
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Table 1 Patient distribution according to tumor stage and location.
Stage Larynx Hypopharynx Oropharynx Oral cavity Unknown primary origin Total
I 3 3 (7%)
II 10 3 13(30%)
III 1 3 1 5 (11%)
IV 6 6 4 4 3 23 (52%)
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When conservation of the larynx is sought, concomi-
tant chemoradiotherapy is mandatory. Tsukuda et al. [5]
assessed feasibility and associated toxicity in elderly UAT
tumor patients. 50 of the patients presenting with stage III
or IV tumor were treated. Grade-3 oral cavity mucositis was
observed in 20% and grade-3 leukocytopenia in 6%. Response
on clinical, endoscopic and radiological assessment was 93%
in stage-III and 54% in stage-IV tumors. The authors con-
cluded that concomitant treatment could be applied in
elderly patients and was well tolerated and effective.
In the present study, 18 patients were treated by
concomitant chemoradiotherapy and assessed. No fatal
complications occurred. Grade-3 mucositis was found in 22%
and grade-3 leukocytopenia in 4%. Global response on clini-
cal, endoscopic and radiological assessment was 88%.
Likewise, results of ﬁrst-intention surgery were assessed
in patients over the age of 80 years, notably by Clayman
et al. [6]. Mean global survival was identical to the actua-
rial survivorship for the general octogenarian population
(P = 0.001). Although the elderly patient group presented
with elevated baseline comorbidity as compared to the
under-80 year-old group, no difference in per- and post-
operative complications rates or treatment efﬁcacy was
found.
In the present study, 17 patients were managed surgi-
cally: 14 in ﬁrst intention, and three by salvage after failure
of radiation therapy. There was no associated mortality.
One patient treated by laryngectomy associated to bilateral
curage developed a spontaneously resolving ﬁstula, and one
developed pneumopathy, treated by antibiotherapy.
Sarini et al. [2], on the other hand, in 273 UAT tumor
patients over 75 years of age, found that treatment option
according to patient age affected prognosis. Surgery or
surgery associated to radiation therapy was signiﬁcantly less
frequently applied in the group of elderly patients, and the
mortality rate was the double of that in the younger age
group: median overall survival was 14months in the elderly
group, versus 20months in the younger age group.
In reality, treatment strategy should be founded on the
full set of factors inﬂuencing the patient’s evolution, and
not on age alone. Pre-operative comorbidity should be
assessed: if it is high, then surgical stress is to be minimized
[7].
First intention surgery associated to complex recon-
struction may thus be feasible in elderly subjects, with
satisfactory results and an acceptable rate of complications.Zabrodsky et al. [7] reported an overall postoperative
complications rate of 63% in elderly patients, similar to that
in a younger population, even though 54% of the elderly
patients presented with at least one comorbidity factor.
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Speciﬁcally, Shaari et al. [8] assessed postoperative
omplications rates in reconstructive surgery by non-
ediculated ﬂap secondary to UAT tumor exeresis in an
lderly population, on a retrospective comparison between
atients aged more or equal to 71vs. less or equal to
0 years, clinically matched for comorbidity factors and
umoral staging. The rate in the former group was 48%,
ersus 57% in the latter, with no difference in type of
omplication; no difference in postoperative complications
ates was found analyzing complications according to defect
ite, comorbidity factor or pre-operative radiation therapy.
he non-pediculated ﬂap reconstruction success rate was
00% in the former group and 94% in the latter. In the
resent series, the postoperative complications rate was
ot higher in the elderly group. One patient showed
ostoperative hematoma requiring surgical drainage. The
ate of medical complications was, however, higher, com-
rising bronchopulmonary and cardiovascular involvement
t equal rates. One patient died of respiratory insufﬁ-
iency.
Blackwell et al. [9] also reported a higher rate of post-
perative medical complications in their older age group,
ut with a success rate equal to that found in the group of
ounger patients.
Sarletti et al. [10], however, showed that higher
SA ranking was associated with higher postoperative
omplications rates. In their series, two patients scored ASA
, 49 ASA 2, 45 ASA 3 and 4 ASA 4. A total of 104 ﬂaps
ere used in 100 patients. The non-pediculated ﬂap recon-
truction success rate was identical to that in the general
opulation of all ages taken together.
Finally, it is clear that, if a poorly adapted treatment
ption (radiation therapy, chemo(radio)therapy, surgery) is
hosen, prognosis in elderly UAT tumor patients will be
ffected: survival did not exceed 19.9% in the speciﬁc case
f patients receiving treatment that was maladapted in
erms of an underestimation of pre-operative comorbidity,
dvanced tumor stage, age and low Karnofsky index
11].
onclusion
pper aerodigestive tract tumor is an aggressive malignancy
equiring aggressive management. All elderly patients
ithout medical contraindications should receive optimal
reatment, without chronological age operating as an exclu-
ion criterion. It is knowledge of comorbidity factors that
ounds treatment options and adaptation.
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